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Abstract
Effective administration of traditional cytotoxic chemotherapy is often limited by off-target 
toxicities. This clinical dilemma is epitomized by cisplatin, a platinating agent that has potent 
antineoplastic activity due to its affinity for DNA and other intracellular nucleophiles. Despite its 
efficacy against many adult-onset and pediatric malignancies, cisplatin elicits multiple off-target 
toxicities that can not only severely impact a patient’s quality of life, but also lead to dose 
reductions or the selection of alternative therapies that can ultimately affect outcomes. Without an 
effective therapeutic measure by which to successfully mitigate many of these symptoms, there 
have been attempts to identify a priori those individuals who are more susceptible to developing 
these sequelae through studies of genetic and nongenetic risk factors. Older age is associated with 
cisplatin induced ototoxicity, neurotoxicity and nephrotoxicity. Traditional genome-wide 
association studies have identified single nucleotide polymorphisms in ACYP2 and WFS1 
associated with cisplatin-induced hearing loss. However, validating associations between specific 
genotypes and cisplatin-induced toxicities with enough stringency to warrant clinical application 
remains challenging. This review summarizes the current state of knowledge with regard to 
specific adverse sequelae following cisplatin-based therapy with a focus on ototoxicity, 
neurotoxicity, nephrotoxicity, myelosuppression and nausea/emesis. We discuss variables (genetic 
and nongenetic) contributing to these detrimental toxicities, and currently available means to 
prevent or treat their occurrence.
Introduction
Cisplatin and the platinating agents represent one of the most widely used and successful 
groups of cytotoxic drugs worldwide. Each year, more than 5.8 million patients are 
diagnosed with cancers for which first-line therapy potentially includes platinating agents 
(colon, rectum, cervix, endometrium, bladder, stomach, head and neck, lung, esophagus, 
pancreas, osteosarcoma, ovary, testis, and childhood cancers) (1). Although cisplatin elicits 
potent antineoplastic activity through the formation of DNA crosslinks (2), the agent also 
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triggers several severe off-target toxicities (Table 1), some of which affect patients acutely 
and resolve after treatment, and some which display little reversibility (2, 3). Although not 
the focus of this review, mechanisms by which cisplatin elicits these toxicities are listed in 
Table 1. For a more comprehensive description, refer to previous reviews for ototoxicity (4–
7); neurotoxicity (8, 9); nephrotoxicity (10–12); myelosuppression (13); and nausea/emesis 
(14, 15).
Due to improved survival rates, most notably in testicular cancer and in pediatric 
malignancies, there are a significant number of survivors living with these severe adverse 
sequelae that affect quality of life. The non-uniformity of these toxicities in patient 
populations has been the subject of much research in efforts to circumvent their occurrence. 
Figure 1 provides an overview of nongenetic risk factors contributing to cisplatin-induced 
toxicities. Of particular interest is the association between older age and an increased 
susceptibility to several cisplatin-induced toxicities. Although the exact mechanisms of this 
association have not been explicitly studied, it is known that drug clearance can decrease 
with age, particularly when elimination is mediated by renal clearance (16). Since cisplatin 
is eliminated predominantly through the kidney, and is also known to be highly nephrotoxic, 
the agent ultimately reduces the ability for platinum to be excreted from the body (10), 
thereby increasing the likelihood of developing cisplatin-induced toxicities. Further, it is not 
surprising that older adults are associated with cisplatin-induced ototoxicity and 
neurotoxicity because these individuals often experience age-related hearing loss/tinnitus 
(17, 18) and paresthesias/neuropathies (19, 20), and the addition of cisplatin will likely 
exacerbate symptoms.
Variability in patient response can also be explained in part by pharmacogenomics, which 
aims to provide the foundation for genetically guided treatment regimens that maximize 
efficacy and minimize toxicity. Initially developed from candidate gene approaches, 
advances in genomic sequencing technologies over the past decade have enabled agnostic 
genome-wide analyses of patient populations characterized for specific drug response 
phenotypes. Thus, pharmacogenomics has elucidated genetic variability as a key 
determinant in both therapeutic benefit and potential toxicities likely to be experienced 
during cisplatin-based chemotherapy. One of the challenges in pharmacogenomics is that 
most cancers are treated with a multi-drug regimen making it difficult to ascertain the 
genetic variants associated with a specific chemotherapeutic toxicity. This is the case for 
cisplatin, however some toxicities (i.e. ototoxicity and nephrotoxicity) are primarily due to 
cisplatin; therefore the genetic variants identified are most likely associated with cisplatin 
exposure. However, understanding both the functional significance and clinical application 
of these findings remains elusive. Therefore, this review will highlight nongenetic and 
genetic risk factors contributing to cisplatin-induced toxicities, and provide recent data on 
novel therapeutic strategies by which to reduce adverse effects.
Ototoxicity
Cisplatin is associated with irreversible, bilateral sensorineural hearing loss that occurs at a 
much higher rate than other ototoxic drugs. Reports indicate that up to 75–80% of patients 
may experience some degree of hearing loss and 13–18% may develop severe-to-profound 
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hearing loss (21–23). In addition, approximately 40% of cisplatin-treated patients (23) 
experience some degree of tinnitus, which occurs at a significantly higher rate than either the 
general population (15%; (24)), or in comparable cancer patients not given cisplatin-based 
chemotherapy (12%; (25)). The frequency of severe tinnitus is also markedly increased in 
cisplatin-treated patients (13–22%; (23, 25)) with one study noting that 42% of patients 
report tinnitus as a major symptom after dose-intensive cisplatin chemotherapy (25). In 
contrast, severe tinnitus occurs in only 1–2% of the general population (24). Further, cancer 
survivors with hearing loss, tinnitus, and neuropathy are more likely to report poorer quality 
of life than those with neuropathy only (26). Another investigation reported worse perceived 
stress among cancer survivors with tinnitus (27).
Although nongenetic risk factors for cisplatin-associated ototoxicity (CAO) have been 
identified (Figure 1), previous studies have focused almost exclusively on hearing loss 
susceptibility. Further, there have been conflicting results with regard to the importance of 
noise exposure and cumulative cisplatin dose on hearing loss (23, 28, 29). However, in 
pediatric cancer patients, males appear to be more susceptible to cisplatin-induced hearing 
loss than females (p=0.005; (29)). Hypertension has also been identified as a potential risk 
factor for hearing loss in testicular cancer patients, with the association remaining significant 
when controlling for age and cisplatin dose (p=0.0066; (23)).
Recently, the FDA granted sodium thiosulfate (STS) “fast-track designation” to prevent 
cisplatin-related hearing loss in pediatric patients diagnosed with hepatoblastoma based on 
the results of a clinical trial of 109 pediatric hepatoblastoma patients in which 20 g/m2 STS 
was administered intravenously 6 hours after the discontinuation of cisplatin for four 
preoperative and two postoperative courses. Not only did STS treatment reduce grade 1 or 
higher hearing loss incidence by 48% (18 of 55 children (33%) in the cisplatin-STS group 
experienced hearing loss compared to 29 of 46 (63%) in the cisplatin-alone group; relative 
risk, 0.52; 95% confidence interval [CI]: 0.33 to 0.81; p=0.002), but cisplatin-STS conferred 
overall and event-free survival rates comparable to those who did not receive the protective 
agent (30). However, of the 16 serious adverse reactions experienced by patients, 8 were 
likely attributed to STS, including two grade 3 infections, two grade 3 neutropenias, one 
grade 3 anemia leading to transfusion, and two tumor progressions. In addition, the 
otoprotective effect of STS was associated with a large sodium load that must be considered 
in planning therapy. The investigators also cautioned that, despite the use of prophylactic 
antiemetic agents, STS remained emetogenic. These adverse events are in accord with prior 
experiences that note the frequency and severity of STS toxicities (31), and the agent must 
be administered with considerable caution. Although STS has demonstrated potential in the 
pediatric setting among a small subgroup of cancer patients, there has yet to be a large, 
multi-institutional study in adult patients, thereby limiting the potential applicability of the 
agent. Consequently, there remains no FDA approved agent to reduce ototoxicity for the vast 
majority of patients who receive cisplatin.
A number of pharmacogenetics studies have been conducted to identify CAO risk-conferring 
genotypes (summarized in Supplementary Table 1). In a study (32) that utilized a platform 
containing primarily single nucleotide polymorphisms (SNPs) in metabolizing genes, 
genetic variants in TPMT (rs12201199) and COMT (rs9332377) were identified that 
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prompted the FDA to revise their label recommendations in 2012 for pediatric patients given 
cisplatin. However, the modification was rescinded in 2015 due to conflicting evidence of 
association between TPMT genetic variants and cisplatin-induced hearing loss provided by 
two replication studies and a meta-analysis (33–35). The lack of reproducibility in 
pharmacogenomic studies related to cisplatin is likely due to genetic heterogeneity as well as 
heterogeneity in treatment protocols and population substructures, small sample sizes, and 
the use of cranial radiation in combination with cisplatin which could substantially increase 
the likelihood of CAO due to its ototoxic effects (36). Specimen type, handling, sequencing 
method, gene calling, as well as the method of assessment of the particular toxicity being 
studied could also contribute to the lack of reproducibility. This points to the importance of 
replication of these pharmacogenomic studies.
Technological advances have enabled agnostic, genome-wide study designs to identify 
contributing SNPs associated with a selected trait. Contrary to candidate gene studies, such 
alleles are not limited by a priori hypotheses of loci that generally reside in exonic genomic 
regions. If fact, the majority of disease-associated variants identified from genome-wide 
association studies (GWAS) reside in intergenic regions associated with transcriptional 
regulatory mechanisms including expression quantitative trait loci (eQTL) known to 
influence gene expression (37, 38). Chemotherapeutic drug susceptibility-associated SNPs, 
including those for cisplatin-induced cytotoxicity, are more likely to be eQTLs and be 
associated with the expression levels of multiple genes (39).
The first GWAS of CAO in 238 pediatric brain tumor patients identified an association with 
a genetic variant in ACYP2 (rs1872328, hazard ratio (HR)=4.5, 95% CI 2.63–7.69, p=3.9 × 
10−8), and results were replicated in a second cohort of 68 pediatric patients (40). Further, 
increased ACYP2 expression highly correlated with cisplatin sensitivity in lymphoblastoid 
cell lines in vitro (p=6.5 × 10−5), but the genotype at the SNP rs1872328 position was not 
associated with cisplatin sensitivity in vitro, nor was it related to expression of ACYP2 and 
other genes 300 kb within this index SNP. Nevertheless, three studies have replicated this 
association with cisplatin-induced hearing loss in 156 osteosarcoma patients (41), 149 
pediatric cancer patients (42) and 229 testicular cancer patients (43). ACYP2 encodes for an 
enzyme that catalyzes phosphate hydrolysis in membrane pumps, most notably the Ca2+/
Mg2+ ATPase from the sarcoplasmic reticulum of skeletal muscle (44). Importantly, ACYP2 
is expressed in the cochlea for ATP-dependent Ca2+ signaling that is critical for hair cell 
development and has been directly implicated in hair cell damage (45, 46), providing a 
rationale for its association with CAO.
The first GWAS of CAO in adult-onset cancer in 511 testicular cancer survivors identified a 
genome-wide significant SNP (rs62283056; p=1.4 × 10−8) in the first intron of Mendelian 
deafness gene WFS1 (wolframin ER transmembrane glycoprotein) (47). This finding was 
replicated in a Canadian study of 229 testicular cancer patients when evaluating the same 
phenotype, i.e., the geometric mean of hearing thresholds at 4–12 kHz (p=5.67 × 10−3, OR = 
3.2), although it was not replicated using a phenotype of audiologist-defined hearing loss 
(43). This difference in statistical significance based on the definition of hearing loss is 
important to note because it indicates that the same genotype can having varying levels of 
statistical association with a phenotype of interest based on how the trait is defined by the 
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investigators. Nevertheless, the SNP is an eQTL for WFS1 based on the Genotype-Tissue 
Expression (GTEx) project, with the risk (and minor) allele being associated with lower 
gene expression in several human tissues. Using an independent cohort from BioVU (a 
large, de-identified DNA biobank linked to a clinical data warehouse), WFS1 was associated 
with ICD-9 derived codes for hearing loss. In a meta-analysis of this GWAS and the GWAS 
that initially identified ACYP2 (40), rs62283056 in WFS1 remained the top signal. However, 
the meta-analysis did not support the ACYP2 variant rs1872328 as being significantly 
associated with adult-onset cancer CAO. Thus, functional validation studies of both WFS1 
and ACYP2 using experimental methods are warranted.
Neurotoxicity
Cisplatin-based therapy is associated with peripheral neuropathy (manifested as tingling, 
numbness, weakness, or burning pain) that occurs in about 36–38% of patients (48, 49). 
Predominantly affecting sensory nerves, cisplatin-induced peripheral neuropathy (CisIPN) 
has been described as a dose-dependent phenomenon, as most cases do not occur until a 
threshold cumulative dose of 300 mg/m2 is reached (50), and almost all patients receiving a 
cumulative dose of 500–600 mg/m2 have objective evidence of nerve damage (51). In 
addition, patients may also experience coasting, which is a persistent worsening of 
symptoms several months after treatment completion (52). The severity of neurotoxicity may 
also be correlated with serum platinum levels, as shown by Sprauten et al. (53) who 
demonstrated that long term serum platinum levels are significantly associated with the 
severity of neurotoxicity 5 to 20 years after cisplatin treatment, and the relationship remains 
significant after adjustment for initial cisplatin dose.
Depending on neuropathy severity, patients can experience a significant reduction in overall 
quality of life, with a strong negative correlation between CisIPN and self-reported health 
(OR = 0.56; p=2.6 × 10−9) demonstrated in 680 cisplatin-treated testicular cancer survivors 
(48). There was also a strong negative correlation of CisIPN with physical activity 
(OR=0.72; p=0.02), and a strong positive correlation with weight gain since therapy (OR per 
Δkg/m2=1.05; p=0.004). Since this investigation was cross-sectional, causal inferences could 
not be made, and a longitudinal design would help determine whether neuropathy deters 
from physical activity, and thus promotes weight gain. In a multivariate model, variables 
significantly related to cisplatin-induced neuropathy included age at diagnosis (OR/yr=1.06, 
p=2 × 10−9), smoking (OR=1.54, p=0.004), excess drinking (OR=1.83, p=0.007), and 
hypertension (OR=1.61, p=0.03) (Figure 1). Currently, there are no effective treatments to 
prevent or reduce the severity of neuropathy induced by cisplatin or other antineoplastic 
agents, but duloxetine is moderately recommended for associated pain (54).
Within the few studies that have investigated genetic susceptibility to long-term cisplatin 
neurotoxicity, there have been several reported associations involving glutathione-S-
transferases (GSTs), in particular, GSTP1 (55, 56) as well as XPC and ERCC1 (57). None of 
these were found to be significant when evaluated through a GWAS ((48); Supplementary 
Table 2).
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In contrast to hearing loss (a quantitative phenotype), peripheral neuropathy is either 
physician-graded or patient-reported using questionnaires. Using the validated EORTC 
QLQ-CIPN20 questionnaire with 680 cisplatin-treated testicular cancer survivors, there were 
no genome-wide significant associations (48). However, using PrediXcan (58), a gene-based 
computational method that uses reference transcriptome (genotype-gene expression) data to 
generate models to ‘impute’ gene expression levels from genotype data and associate the 
predicted gene expression with phenotypes of interest, lower expression of RPRD1B was 
identified as significantly associated with CisIPN. An evaluation of 18,620 genotyped 
patients from BioVU demonstrated a relationship between RPRD1B gene expression and 
polyneuropathy due to drugs. RPRD1B is of particular interest because defects in its 
expression or knockdown have been shown to inhibit DNA repair mechanisms that resolve 
cisplatin-induced lesions (59). Further, RPRD1B knockdown in human breast carcinoma 
cells potentiates cisplatin sensitivity (60). As illustrated in this example, the advantage of 
PrediXcan analysis is that it substantially reduces multiple corrections in comparison to 
SNP-based GWAS, while also providing a directionality of effect between gene expression 
and phenotype.
Nephrotoxicity
The kidneys are particularly susceptible to toxicity since cisplatin is eliminated 
predominantly through renal clearance (11). Consequently, impaired renal function is found 
in approximately 25–35% of patients after a single cisplatin dose (61). In spite of preventive 
measures (i.e., intense intravenous hydration during cisplatin administration), successive 
treatment courses can potentiate a progressive nephrotoxicity that can lead to permanent 
damage (12). Further, cisplatin induces acute kidney injury in approximately 20–30% of 
patients, while hypomagnesemia manifests in 40–100% (12).
In addition to known risk factors for cisplatin-induced renal toxicity such as older age, 
comorbidities, low albumin levels, preexisting kidney disease, and concurrent use of 
nephrotoxic medications (Figure 1) (12), an increasing number of studies have investigated 
the importance of genetic contributions, albeit only in candidate gene studies 
(Supplementary Table 2). A SNP in ERCC1 (8092C>A/rs3212986) has been shown to be 
significantly associated with a reduced risk of cisplatin-induced nephrotoxicity in two 
separate candidate gene studies (62, 63), as well as rs1051740 in EPHX1 (64). In addition, 
two cation transporters vital for cisplatin renal uptake (OCT2/SLC22A2 and CTR1/
SLC31A1; Table 1) have SNPs associated with renoprotection and maintenance of estimated 
glomular filtration rate (rs596881 (OCT2); rs12686377 and rs7851395 (CTR1; (65).
Myelosuppression
As do many antineoplastic agents, cisplatin can profoundly impact hematopoiesis. 
Myelosuppression occurs in 25–30% of patients, particularly when cisplatin doses exceed 50 
mg/m2 (66), and severe myelosuppression develops in approximately 5–6% (13). Cisplatin-
based therapy often has a disproportionate effect on erythrocyte production in comparison 
with other blood cells, resulting in a cumulative, clinically significant anemia (67). The 
increase in oxidative stress that induces other cisplatin-induced adverse sequelae (Table 1) 
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also appears to contribute to bone marrow toxicity (68). While acute myelosuppression is an 
immediate clinical concern, many patients receiving chemotherapy and/or radiotherapy also 
develop residual bone marrow injury, as evidenced by a sustained reduction in hematopoietic 
stem cell reserves that can potentiate long-term hematological complications (69, 70). 
Indeed, two studies have shown statistically significant associations between cumulative 
cisplatin dose and the subsequent development of leukemia (71, 72). In addition, patients 
who have a poor performance status and have had prior chemotherapy exposure are at 
increased risk of hematological complications (Figure 1) (73, 74).
Although the analysis of genetic contributions to cisplatin-induced myelosuppression has 
been limited, a GWAS was undertaken in non-small cell lung carcinoma (NSCLC) patients 
of Han Chinese descent. Two SNPs (rs13014982 and rs9909179) exhibited associations with 
myelosuppression in the discovery and replication sets, but did not reach genome-wide 
significance in the discovery set. Nevertheless, these SNPs retained plausible associations in 
the subsequent meta-analysis of both patient cohorts (rs13014982: p=1.36 × 10−5; 
rs9909179: p=0.001 (75). rs13014982 is located in a gene desert at 2q24.3 (within 500 kb of 
FIGN), limiting its potential genetic significance, but rs9909179 was determined via GTEx 
to be a plausible eQTL for HS3ST3A1 in blood (p=0.03), an enzyme involved in heparan 
sulfate biosynthesis, which may be important in hematopoiesis (76).
Nausea/Emesis
Nausea and emesis are frequently cited as among the most feared complications of 
chemotherapy (14, 77). Although the development of antiemetics has reduced the incidence 
of these toxicities, many patients still experience either acute (within 24 hours), or delayed 
nausea and/or emesis. This is epitomized by cisplatin treatment, as doses of 50 mg/m2 or 
more induce acute nausea and vomiting in > 90% of patients not administered antiemetic 
prophylaxis (14), with 60–90% experiencing delayed nausea/emesis (77). Women have a 
higher susceptibility to developing emesis following cisplatin treatment than men, as shown 
in two separate studies in NSCLC patients (78, 79). Other risk factors for chemotherapy-
induced nausea and vomiting include younger age, history of low alcohol intake, experience 
of emesis during pregnancy, impaired quality of life, and prior chemotherapy exposure 
(Figure 1) (77, 80).
Variation in the susceptibility of patients experiencing emesis following cisplatin 
administration based on genetic ancestry has been noted by Khrunin et al. (81) in which 
Yakuts (North Asians) had a borderline statistically significant difference in developing 
severe emesis compared to Russians of Eastern European descent (38% vs 25%; p=0.061). 
Importantly, severe emesis in Yakuts was independently associated with two polymorphisms 
in the CYP2E1 gene, but was only associated with the GSTT1-null genotype in Eastern 
European Russians.
Trends in Relevant Pharmacogenomic Studies
Although analyses of genetic predisposition to cisplatin-induced toxicities are relatively 
novel with most studies published within the last decade, several important trends have 
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emerged that may guide future investigations. Of the 36 genetic studies analyzed in the 
present review, an overwhelming majority investigated ototoxicity (n=26), with 
neurotoxicity the next most common toxicity (n=5). Thus, ototoxicity was the only toxicity 
to have genetic associations investigated for validity through multiple independent 
replication studies, and many analyses failed to confirm previously identified SNPs 
(Supplementary Table 1). Although ototoxicity is a prominent cisplatin-related adverse 
event, other toxicities also occur in a relatively high proportion of patients (Table 1) and can 
result in the administration of doses that are sub-optimal for antineoplastic efficacy. Further, 
most investigations have relied on a candidate gene approach, and only four GWAS have 
been performed (40, 47, 59, 75). GWAS have the potential to identify causal SNPs in genes 
agnostically, but require large cohorts of patients treated with the same regimen and 
uniformly phenotyped for toxicity.
In addition to the disproportionate number of studies that have used candidate gene 
approaches to probe cisplatin-induced toxicities, few investigations have evaluated these 
adverse sequelae in cohorts not predominantly/exclusively of European ancestry. This 
observation mirrors the lack of ancestral diversity represented in GWAS of 
chemotherapeutic toxicities despite known differences in allele frequencies and effect sizes 
among individuals of differing ancestries (82). One reason for this is that several GWAS 
were performed in testicular cancer survivors, a disease that disproportionately affects white 
males (83). As such, genetic variants that are associated with varying levels of cisplatin 
sensitivity in European-based studies may not be relevant in patients of other genetic 
ancestries, thereby promoting a gap in health disparities. Although these slight genetic 
variations may appear to be subtle nuances among heterogeneous patient populations, 
finding causal associations of adverse sequelae is a hallmark paradigm of precision 
medicine, and may eventually enable treatment regimens and doses to be tailored 
specifically to the individual patient to maximize treatment efficacy while limiting toxicities.
Future Directions
Based on the analysis of previous pharmacogenomic studies of cisplatin-induced toxicities, 
it is apparent that investigators should expand the search of relevant genetic variants beyond 
ototoxicity and patient populations of European ancestry. Further, the lack of reproducibility 
found in candidate gene studies of ototoxicity underscores the importance of genome-wide 
studies with large cohorts of uniformly treated patients to comprehensively examine the 
entire genome for potential associations with other cisplatin-induced toxicities. Regardless 
of the in silico approach used to identify genetic variants of potential interest, it is paramount 
that associations are functionally validated in vitro and/or in vivo (84). Through this critical 
step, the biological significance of the identified genetic variants can be definitively 
ascertained. Moreover, physiological validation of the genetic architecture underlying 
different cisplatin-induced toxicities may potentiate the discovery of novel drug targets that 
can mitigate the adverse effects, thereby reducing its overall morbidity. These 
mechanistically based therapeutic strategies may ultimately be leveraged to identify novel 
drug targets that can reduce selected toxicities without inhibiting antineoplastic efficacy.
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The Platinum Study examines the long-term effects of cisplatin treatment in cured testicular 
cancer survivors to comprehensively evaluate the toxicities associated with cisplatin (1). 
Since testicular cancer generally affects men of European descent, it is inherently limited in 
its ability to examine cisplatin toxicities in different genetic ancestries. Current plausible 
alternative cohorts include the St. Jude LIFE Study and the multi-institutional Childhood 
Cancer Survivor Study, initiatives designed to examine the long-term effects of radiotherapy 
and chemotherapy in pediatric cancer survivors (85, 86). However, in both endeavors, only a 
small subset of patients received cisplatin. Therefore, the development of patient cohorts of 
varying genetic backgrounds and cancer diagnoses is required to fully characterize the 
genetic architecture of cisplatin-induced toxicities.
Once viable predictive biomarkers of cisplatin-induced toxicities have been established, 
additional preclinical and clinical studies will be required to determine how to optimally 
apply this information to minimize cisplatin-induced toxicities while maintaining therapeutic 
efficacy. In addition to establishing a priori which patients may likely require either dose 
reductions or alternative therapy, these patients may also serve as an ideal cohort to examine 
novel platinum analogs with a reduced toxicity profile (87), provided comparable 
antineoplastic efficacy has been established.
Conclusion
Cisplatin-induced toxicities are numerous and high in frequency, making identification of 
patients likely to experience adverse events critical for optimizing clinical care. 
Understanding non-genetic risk factors for off-target toxicities is informative for physicians 
because this knowledge can be used to educate patients on their likelihood of experiencing 
adverse events during and after cisplatin-based therapy. Since cisplatin is a highly used 
antineoplastic agent, such information is relevant for the treatment of multiple adult-onset 
and pediatric malignancies. Further, it is important to emphasize that a growing number of 
patients treated with cisplatin-based chemotherapy are being cured of their disease (i.e. 
hepatoblastoma, HPV+ oropharyngeal cancer, medulloblastoma, osteosarcoma, and 
testicular cancer). Cisplatin is also finding use in the neoadjuvant setting for multiple tumor 
types, particularly bladder cancer (88, 89), indicating that there will be an increasing number 
of patients exposed to cisplatin who will live many years after their initial cancer diagnosis. 
Consequently, understanding the underlying basis for cisplatin toxicity has an emerging role 
in the management of this growing patient population. Given that many patients’ tumors and 
germline DNA are now being sequenced, understanding genetic predisposition to cisplatin 
toxicity will provide a basis for a personalized medicine approach to managing its toxicity.
Although cisplatin-induced toxicities have been well-characterized, the importance of 
genetic variation in the occurrence of adverse reactions is only now becoming appreciated 
through modern pharmacogenomic approaches. Nevertheless, a diversification of studies in 
regards to toxicity types and patient cohorts is needed, with greater emphasis on 
implementing genome-wide analyses followed by independent replication and functional 
validation. Only then can these associations be considered plausible biomarkers of cisplatin-
induced toxicity that can be harnessed to tailor treatment regimens to individual patients.
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Figure 1. 
Nongenetic risk factors that may predispose patients to developing adverse events following 
cisplatin-based therapy. Where relevant, risk factors are denoted as being either continuous 
or categorical variables based on how they were examined for association with the given 
toxicity.
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ela
ye
d s
ym
pto
ms
 
o
cc
u
r 
in
 6
0–
90
%
 o
f p
at
ie
nt
s u
nd
er
 th
e 
sa
m
e 
co
n
di
tio
ns
 (7
7).
Pe
rtu
rb
s t
he
 li
ni
ng
 o
f t
he
 g
as
tr
oi
nt
es
tin
al
 tr
ac
t, 
w
hi
ch
 su
bs
eq
ue
nt
ly
 
pr
om
ot
es
 C
a2
+ -
de
pe
nd
en
t e
x
o
cy
tic
 re
le
as
e 
of
 se
ro
to
ni
n 
fro
m
 
en
te
ro
ch
ro
m
af
fin
 c
el
ls 
(15
). S
uc
ce
ssf
ul 
bin
din
g o
f s
ero
ton
in 
to 
its
 re
ce
pto
rs 
o
n
 th
e 
va
ga
l a
ffe
re
nt
 n
eu
ro
ns
 a
ct
iv
at
es
 th
e 
ch
em
or
ec
ep
to
r t
rig
ge
r z
on
e 
an
d 
v
o
m
iti
ng
 c
en
te
r t
ha
t p
ro
m
ot
e 
th
e 
in
iti
at
io
n 
of
 th
e 
em
et
og
en
ic
 re
sp
on
se
.
O
to
to
xi
ci
ty
•
 Ir
re
v
er
sib
le
 se
ns
or
in
eu
ra
l 
he
ar
in
g 
lo
ss
•
 T
in
ni
tu
s
So
m
e 
de
gr
ee
 o
f h
ea
rin
g 
lo
ss
 o
cc
ur
s i
n 
75
–
80
%
 o
f p
at
ie
nt
s (
5,
 
23
), w
hil
e 1
3–
18
% 
de
v
el
op
 se
v
er
e-
to
-p
ro
fo
un
d 
he
ar
in
g 
lo
ss
 
(4–
6).
Sy
m
pt
om
s o
f t
in
ni
tu
s o
cc
ur
 in
 
ap
pr
ox
im
at
el
y 
40
%
 o
f p
at
ie
nt
s (
6),
 w
ith
 
13
–2
2%
 ex
pe
rie
nc
in
g 
se
v
er
e 
tin
ni
tu
s (
6,
 
8).
In
cr
ea
se
s r
ea
ct
iv
e 
o
x
yg
en
 sp
ec
ie
s c
on
ce
nt
ra
tio
ns
 a
nd
 d
ep
le
te
s a
nt
io
xi
da
nt
s 
u
se
d 
fo
r d
et
ox
ifi
ca
tio
n 
(90
–
92
). C
isp
lat
in 
als
o a
cti
v
at
es
 b
ig
 c
on
du
ct
an
ce
 
po
ta
ss
iu
m
 c
ha
nn
el
s i
n 
sp
ira
l l
ig
am
en
t f
ib
ro
cy
te
s (
SL
Fs
), w
hic
h a
dv
er
se
ly
 
di
sr
up
t t
he
 e
le
ct
ro
ch
em
ic
al
 g
ra
di
en
t w
ith
in
 c
el
ls 
an
d 
tri
gg
er
 a
po
pt
os
is 
(93
). 
Th
e 
co
ch
le
a 
re
ta
in
s c
isp
la
tin
 fo
r m
on
th
s t
o 
ye
ar
s a
fte
r t
re
at
m
en
t, 
w
ith
 
ac
cu
m
u
la
tio
n 
be
in
g 
pa
rti
cu
la
rly
 h
ig
h 
in
 th
e 
str
ia
 v
as
cu
la
ris
, t
he
 S
LF
-
co
n
ta
in
in
g 
re
gi
on
 v
ita
l f
or
 th
e 
m
ai
nt
en
an
ce
 o
f e
nd
ol
ym
ph
 io
ni
c 
co
m
po
sit
io
n 
(94
). P
lat
inu
m-
DN
A
 a
dd
uc
ts 
ha
v
e 
be
en
 d
et
ec
te
d 
in
 th
e 
ha
ir 
ce
lls
 o
f t
he
 c
oc
hl
ea
 a
nd
 th
e 
m
ar
gi
na
l c
el
ls 
of
 th
e 
str
ia
 v
as
cu
la
ris
. S
in
ce
 
th
es
e 
ce
lls
 d
o 
no
t p
ro
lif
er
at
e,
 p
la
tin
at
io
n 
of
 m
ito
ch
on
dr
ia
l D
NA
 (m
tD
NA
) i
s 
co
n
sid
er
ed
 re
sp
on
sib
le
 fo
r t
ox
ic
ity
 (4
,
 
9).
N
eu
ro
to
xi
ci
ty
 (P
eri
ph
era
l N
eu
rop
ath
y)
•
 P
er
sis
te
nt
 p
er
ip
he
ra
l s
en
so
ry
 
n
eu
ro
pa
th
y
•
 R
ed
uc
ed
 p
hy
sic
al
 a
ct
iv
ity
 a
nd
 
w
ei
gh
t g
ai
n
Pe
rip
he
ra
l s
en
so
ry
 n
eu
ro
pa
th
y 
oc
cu
rs
 in
 
36
–3
8%
 o
f p
at
ie
nt
s. 
(48
,
 
49
). A
lm
os
t a
ll 
pa
tie
nt
s w
ho
 re
ce
iv
e 
a 
cu
m
u
la
tiv
e 
do
se
 o
f 
50
0–
60
0 
m
g/
m
2  
ex
pe
rie
nc
e 
ne
rv
e 
da
m
ag
e 
(33
).
A
cc
um
ul
at
es
 in
 th
e 
do
rs
al
 ro
ot
 g
an
gl
ia
 o
f t
he
 sp
in
al
 c
or
d 
an
d 
pe
rip
he
ra
l 
n
eu
ro
n
s 
v
ia
 p
as
siv
e 
di
ffu
sio
n 
or
 m
et
al
 tr
an
sp
or
te
rs
. F
o
rm
s 
D
N
A
 a
dd
uc
ts 
an
d 
in
hi
bi
ts 
D
NA
 re
pa
ir 
pa
th
w
ay
s t
ha
t u
lti
m
at
el
y 
in
du
ce
 p
53
-m
ed
ia
te
d 
ap
op
to
sis
 v
ia
 B
ax
 a
ct
iv
at
io
n 
(95
). T
he
 af
fin
ity
 o
f c
isp
la
tin
 fo
r m
tD
N
A
 m
ay
 
he
lp
 ex
pl
ai
n 
th
e 
cl
in
ic
al
 q
ua
nd
ar
y 
of
 c
oa
sti
ng
, a
s t
he
 a
bs
en
ce
 o
f t
he
 
n
u
cl
eo
tid
e 
ex
ci
sio
n 
re
pa
ir 
(N
ER
) i
n t
he
 m
ito
ch
on
dri
a c
ou
ld 
po
ten
tia
te 
a 
gr
ad
ua
l a
ttr
iti
on
 o
f m
ito
ch
on
dr
ia
, s
ub
se
qu
en
tly
 re
du
ci
ng
 A
TP
 le
v
el
s t
ha
t 
n
eu
ro
n
s 
re
qu
ire
 to
 m
ai
nt
ai
n 
th
ei
r f
un
ct
io
na
l a
ct
iv
ity
 (9
6).
M
ye
lo
su
pp
re
ss
io
n
•
 C
yt
op
en
ia
s
•
 R
es
id
ua
l b
on
e 
m
ar
ro
w
 in
jur
y 
an
d 
re
du
ct
io
n 
in
 h
em
at
op
oi
et
ic
 
st
em
 c
el
l r
es
er
ve
s
•
 P
ot
en
tia
l s
us
ce
pt
ib
ili
ty
 to
 
se
co
n
da
ry
 le
uk
em
ia
B
et
w
ee
n 
25
–3
0%
 o
f p
at
ie
nt
s d
ev
el
op
 
sy
m
pt
om
s o
f m
ye
lo
su
pp
re
ss
io
n,
 w
hi
le
 5
–
6%
 (6
6) 
are
 di
ag
no
sed
 w
ith
 se
v
er
e 
m
ye
lo
su
pp
re
ss
io
n.
El
ic
its
 b
ot
h 
ge
no
to
xi
c 
ef
fe
ct
s a
nd
 o
xi
da
tiv
e 
st
re
ss
 to
 d
ep
le
te
 b
lo
od
 
co
u
n
ts
(68
). P
at
ie
nt
s m
ay
 a
lso
 d
ev
el
op
 re
sid
ua
l b
on
e 
m
ar
ro
w
 in
jur
y i
n w
hic
h 
th
er
e 
is 
a 
su
sta
in
ed
 re
du
ct
io
n 
in
 h
em
at
op
oi
et
ic
 st
em
 c
el
l r
es
er
ve
s 
du
e 
to
 
se
lf-
re
ne
w
al
 im
pa
irm
en
t (
69
,
 
70
).
N
ep
hr
ot
ox
ic
ity
•
 A
cu
te
 k
id
ne
y 
in
jur
y
•
 H
yp
om
ag
ne
se
m
ia
•
 P
er
m
an
en
t k
id
ne
y 
da
m
ag
e
A
cu
te
 k
id
ne
y 
in
jur
y o
ccu
rs 
in 
20
–3
0%
 of
 
pa
tie
nt
s (
12
). H
yp
om
ag
ne
sem
ia 
ma
nif
est
s 
in
 4
0–
10
0%
 o
f p
at
ie
nt
s.
A
ct
iv
e 
tr
an
sp
or
t t
hr
ou
gh
 O
ct
2 
an
d 
Ct
r1
 (9
7,
 
98
) i
nd
uc
es 
tox
ici
ty 
pri
ma
ril
y 
in
 th
e 
re
na
l p
ro
xi
m
al
 tu
bu
le
s (
11
). M
ec
ha
nis
ms
 of
 da
ma
ge
 in
clu
de
 
en
do
pl
as
m
ic
 re
tic
ul
um
 st
re
ss
 a
nd
 m
ito
ch
on
dr
ia
l d
ys
fu
nc
tio
n 
le
ad
in
g 
to
 
o
x
id
at
iv
e 
st
re
ss
, a
s 
w
el
l a
s i
nf
la
m
m
at
io
n 
m
ed
ia
te
d 
by
 tu
m
or
 n
ec
ro
sis
 fa
ct
or
 
an
d 
ot
he
r c
he
m
ok
in
es
 (1
1,
 
12
).
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